Phase 1 × Lymphoma, Large B-Cell, Diffuse × Bortezomib × Clear all
NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Swiss Cancer Institute

Phase 1 Completed
18 enrolled
NCT00671112 2015-10-28

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
30 enrolled
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
NCT00006098 2013-06-18

PS-341 in Treating Patients With Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled
NCT00054483 2013-05-16

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
69 enrolled
NCT00348985 2013-05-03

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
55 enrolled
NCT00004002 2012-11-09

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

NYU Langone Health

Phase 1 Completed
NCT00006362 2011-08-03

PS-341 in Treating Patients With Advanced Cancer

Mayo Clinic

Phase 1 Completed